Top Markets
Coin of the day
Kyverna Therapeutics, Inc. Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc.

KYTX
Rangering i aksjer #13173
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Aksjekurs
$8.46
Sist synkronisert: 2026-08-28
Markedsverdi
$514.33M
Endring (1 dag)
-2.08%
Endring (1 år)
128.03%
Land
US
Handel Kyverna Therapeutics, Inc. (KYTX)

Kategori

Utbytteavkastning for Kyverna Therapeutics, Inc. (KYTX)
Kyverna Therapeutics, Inc. (aksjesymbol: KYTX) sin utbytteavkastning (TTM) per 2026 er: 0
Gjennomsnittlig utbytteavkastning de siste 5 årene: 0.00%
Utbytteavkastning for Kyverna Therapeutics, Inc. (KYTX) fra 2026 til 2026
Utbytteavkastning ved slutten av hvert år (TTM)
År Utbytteavkastning Endre
Ikke nok data for de angitte datoene.
Utbytteavkastning (TTM) for lignende selskaper eller konkurrenter
Selskap Utbytteavkastning Land
0.00%
US
0.00%
NL
3.12%
AU
0.00%
US
0.00%
CH